James K Mangan, MD, PhD, discusses investigational approaches to the treatment of acute leukemia and provides a review of standards for AML and ALL, as well as such novel therapies as the TKIs FLT3-ITD and dasantinib, gemtuzumab, CTL-019 and blinatumomab.
Related Links
Published
August 14, 2014
Created by
BROADCASTMED